In vivo animal studies have shown that either pharmacological activation or genetic regulation of AMPK had preventive, curative, and potential reversal effects on pain in models of nerve injury, chemotherapy-induced peripheral neuropathy, postsurgical pain, inflammatory pain, and diabetic neuropathy [12]. Here, PRKAA1 is linked to diabetic neuropathy.